<DOC>
	<DOCNO>NCT02081300</DOCNO>
	<brief_summary>The purpose study determine safety efficacy oral testosterone undecanoate formulation use testosterone-replacement therapy men low testosterone .</brief_summary>
	<brief_title>Safety Efficacy Oral LPCN 1021 Men With Low Testosterone Hypogonadism</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Eunuchism</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Antineoplastic Agents , Hormonal</mesh_term>
	<mesh_term>Hormones , Hormone Substitutes , Hormone Antagonists</mesh_term>
	<criteria>1 . Documented diagnosis primary hypogonadism ( congenital acquire ) hypogonadotropic hypogonadism ( congenital acquire ) . 2 . Serum total testosterone &lt; 300 ng/dL base 2 consecutive blood sample A subject eligible study participation meet follow criterion . 1 . History significant sensitivity allergy androgen , castor oil product excipients . 2 . Clinically significant finding prestudy examination . 3 . Abnormal prostate digital rectal examination ( DRE ) palpable nodule ( ) IPSS score &gt; 19 point . 4 . Body mass index ( BMI ) â‰¥ 38 kg/m2 . 5 . Clinically significant abnormal laboratory value 6 . Positive test result hepatitis A virus immunoglobulin M ( HAVIgM ) , hepatitis B surface antigen ( HBsAg ) hepatitis C virus antibody ( HCV Ab ) human immunodeficiency virus antibody ( HIV Ab ) . 7 . History seizure convulsion , include febrile , alcohol drug withdrawal seizure . 8 . History gastric surgery , cholecystectomy , vagotomy , bowel resection surgical procedure might interfere gastrointestinal motility , pH absorption . 9 . History clinically significant illness , infection , surgical procedure within 1 month prior study drug administration . 10 . History stroke myocardial infarction within past 5 year . 11 . History , current suspect , prostate breast cancer . 12 . History diagnose , severe , untreated , obstructive sleep apnea . 13 . History abuse alcohol drug substance opinion investigator within previous 2 year . 14 . History long QT syndrome unexplained sudden death first degree relative ( parent , sibling , child ) . 15 . Concurrent treatment medication may impact absorption , distribution , metabolism excretion testosterone undecanoate ( TU ) place subject risk treatment testosterone . 16 . Subject partner currently pregnant plan pregnancy course clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Testosterone</keyword>
	<keyword>Male hypogonadism</keyword>
	<keyword>Low testosterone</keyword>
	<keyword>LPCN 1021</keyword>
	<keyword>Androgel</keyword>
	<keyword>Testim</keyword>
	<keyword>Testopel</keyword>
	<keyword>Fortesta</keyword>
	<keyword>Axiron .</keyword>
	<keyword>Hypogonadism</keyword>
	<keyword>Eunuchism</keyword>
	<keyword>Gonadal Disorders</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Testosterone enanthate</keyword>
	<keyword>Testosterone undecanoate</keyword>
	<keyword>Testosterone 17 beta-cypionate</keyword>
	<keyword>Methyltestosterone</keyword>
	<keyword>Androgens</keyword>
	<keyword>Hormones</keyword>
	<keyword>Hormones , Hormone Substitutes , Hormone Antagonists</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Antineoplastic Agents , Hormonal</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Anabolic Agents</keyword>
</DOC>